Knowlton Gwendolyn Binderscholl Net Worth & Insider Trades

Knowlton Gwendolyn Binderscholl - Chief Technology Officer, Adaptimmune Therapeutics Plc

As of January 16, 2019

What is Knowlton Gwendolyn Binderscholl's Net Worth?

The current estimated net worth of Adaptimmune Therapeutics Plc's Chief Technology Officer, Knowlton Gwendolyn Binderscholl, is estimated to be about $612.98K . Knowlton Gwendolyn Binderscholl owns about 2,487 units of Adaptimmune Therapeutics Plc common stock. In the last 2 years at Adaptimmune Therapeutics Plc, Knowlton Gwendolyn Binderscholl has sold an estimated value of $609.13K worth.

What is Knowlton Gwendolyn Binderscholl's Past Insider Trading?

Knowlton Gwendolyn Binderscholl's largest sale order was 25,000 units , worth over $344.75K on October 2, 2018. In total, Knowlton Gwendolyn Binderscholl has made about 5 transactions over 2 years of their time at Adaptimmune Therapeutics Plc. Knowlton Gwendolyn Binderscholl usually trades in January, with the busiest year in 2018. The most recent transaction was a sale order of 1,514 units , worth over $8.13K on January 16, 2019.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Knowlton Gwendolyn Binderscholl's' Mailing Address?

  • Mailing address is 1903 Carpenter Street Philadelphia PA 19146 PA

Adaptimmune Therapeutics Plc Executive Compensation

Name
Year
Salary
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Adrian Rawcliffe 2020 $574,000 $1,715,346 $378,840 $33,416 $2,701,602
Adrian Rawcliffe 2019 $500,481 $1,427,399 $177,251 $49,912 $2,155,042
Adrian Rawcliffe 2018 $457,011 $730,791 $174,807 $54,775 $1,417,384
Gavin Wood 2020 $337,065 $990,268 $166,847 $73,731 $1,567,911
Helen Tayton-Martin 2020 $454,940 $857,661 $225,195 $23,531 $1,561,327
Helen Tayton-Martin 2019 $435,949 $766,900 $137,324 $30,491 $1,370,664
Helen Tayton-Martin 2018 $408,308 $730,791 $156,178 $22,007 $1,317,284
William Bertrand 2020 $443,456 $857,661 $219,511 $30,485 $1,551,113
William Bertrand 2019 $432,640 $766,900 $136,282 $35,358 $1,371,180
William Bertrand 2018 $416,000 $685,114 $159,120 $35,070 $1,295,304
John Lunger 2020 $400,000 $857,661 $198,000 $31,802 $1,487,463
John Lunger 2019 $366,867 $435,546 $94,542 $35,655 $932,610
John Lunger 2018 $316,958 $602,909 $92,948 $35,07 $1,047,885
Michael Garone 2020 $217,000 - - - $217,000
Michael Garone 2019 $206,500 - - - $206,500
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1621227/000110465921047833/tm212433-2_def14a.htm

What are Adaptimmune Therapeutics Plc's Past Insider Trades?

Adaptimmune Therapeutics Plc's most recent insider trade came on August 1, 2022 by John Lunger who sold 2,983 units worth $5.29K . In the last 6 years, insiders at Adaptimmune Therapeutics Plc have sold an estimated value of $40.15M and bought an estimated value of $526.78M worth of shares. Insider trading is most common in January, with the busiest year in 2018. The most active traders at the company are Adrian Rawcliffe, Chief Executive Officer,  John Lunger, Chief Patient Supply Officer,  and William Charles Bertrand, Chief Operating Officer .

Adaptimmune Therapeutics PLC Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1